skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Panel Roster

(Last updated:May 01, 2014; last reviewed:May 01, 2014)

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Roster
These Guidelines are developed by the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (a Working Group of the Office of AIDS Research Advisory Council).
   
 Panel Co-Chairs  
 John G. Bartlett Johns Hopkins University, Baltimore, MD (term ended December 31, 2013)
 Roy M. Gulick
Weill Medical College of Cornell University, New York, NY (term began January 1, 2014)
 Martin S. Hirsch
Massachusetts General Hospital & Harvard Medical School, Boston, MA (term began January 1, 2014)
 H. Clifford Lane National Institutes of Health, Bethesda, MD
 Executive Secretary  
 Alice K. Pau National Institutes of Health, Bethesda, MD
 Scientific Members  
 Judith Aberg  Icahn School of Medicine of Mount Sinai University, New York, NY
 Adaora Adimora  University of North Carolina, Chapel Hill, NC
 John T. Brooks  Centers for Disease Control and Prevention, Atlanta, GA
 J. Kevin Carmichael  El Rio Specialty Immunology Associates, Tucson, AZ
 Deborah L. Cohan  University of California–San Francisco, San Francisco, CA
 Eric Daar  University of California–Los Angeles, Harbor-UCLA Medical Center, Los Angeles, CA
 Steven G. Deeks  University of California–San Francisco, San Francisco, CA (term ended March 4, 2014)
 Carlos del Rio  Emory University, Atlanta, GA (term ended March 4, 2014)
 Gerald Friedland  Yale University School of Medicine, New Haven, CT
 Joel E. Gallant  Southwest CARE Center, Santa Fe, NM (term ended March 4, 2014)
 Rajesh T. Gandhi  Massachusetts General Hospital & Harvard Medical School, Boston, MD
 Stephen J. Gange  Johns Hopkins University, Baltimore, MD
 Thomas Giordano  Baylor College of Medicine, Houston, TX (term began March 4, 2014)
 Richard Haubrich  University of California–San Diego, San Diego, CA (term began March 4, 2014)
 W. Keith Henry  Hennepin County Medical Center & University of Minnesota, Minneapolis, MN (term ended March 4, 2014)
 Michael D. Hughes  Harvard School of Public Health, Boston, MA
 Peter Hunt  University of California–San Francisco, San Francisco, CA (term began March 4, 2014)
 Bill G. Kapogiannis  National Institutes of Health, Bethesda, MD
 Marla Keller  Albert Einstein College of Medicine, New York, NY (term began March 4, 2014)
 Daniel R. Kuritzkes  Brigham and Women’s Hospital & Harvard Medical School, Boston, MA 
 Jeffrey Lennox  Emory University, Atlanta, GA (term began March 4, 2014)
 Richard W. Price  University of California–San Francisco, San Francisco, CA
 James L. Raper  University of Alabama at Birmingham, Birmingham, AL
 Bret J. Rudy  New York University, New York, NY
 Michael Saag  University of Alabama at Birmingham, Birmingham, AL (term ended March 4, 2014)
 Paul Sax  Brigham and Women’s Hospital & Harvard Medical School, Boston, MA
 Kimberly Scarsi University of Nebraska, Omaha, NE
 Mark Sulkowski  Johns Hopkins University, Baltimore, MD
 Pablo Tebas  University of Pennsylvania, Philadelphia, PA
 Zelalem Temesgen  Mayo Clinic, Rochester, MN
 Phyllis Tien  University of California–San Francisco, San Francisco, CA
 Rochelle Walensky  Massachusetts General Hospital & Harvard Medical School, Boston, MA
 David A. Wohl  University of North Carolina, Chapel Hill, NC
 Community Members  
 Lei Chou  Treatment Action Group, New York, NY
 Paul Dalton  San Francisco, CA (term ended March 4, 2014)
 David Evans  Project Inform, San Francisco, CA
 Danielle Houston  Houston, TX
 Jeff Taylor  AIDS Treatment Activists Coalition, Palm Springs, CA
 Nelson Vergel  Program for Wellness Restoration, Houston, TX
 Members Representing Department of Health and Human Services Agencies
 Victoria Cargill  National Institutes of Health, Rockville, MD
 Laura Cheever  Health Resources and Services Administration, Rockville, MD
 Jonathan Kaplan   Centers for Disease Control and Prevention, Atlanta, GA
 Kendall Marcus  Food and Drug Administration, Silver Spring, MD
 Henry Masur   National Institutes of Health, Bethesda, MD
 Lynne Mofenson   National Institutes of Health, Bethesda, MD
 Kimberly Struble  Food and Drug Administration, Silver Spring, MD
 Acknowledgement  
The Panel would like to acknowledge Sarita D. Boyd and Monica Calderon (Food and Drug Administration) and Lori Gordon (National Institutes of Health) for their assistance in updating the drug interaction tables in the guidelines, and recognize Thomas Uldrick (National Cancer Institute) for his contributions to the discussion on malignancies in the “Initiating Antiretroviral Therapy in Treatment-Naive Patients” section of the guidelines.

Back to Top